|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
Prepublished online as a Blood First Edition Paper on December 12, 2002; DOI 10.1182/blood-2002-07-2201.
CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS
From the Division of Internal Medicine, Department of
Medical and Surgical Sciences, 2nd Chair of Internal Medicine,
University Hospital of Padua, Italy; and Institute for Immunology and
Transfusion Medicine, Ernst-Moritz-Arndt University, Greifswald,
Germany.
Although heparin-induced thrombocytopenia (HIT) is a known
complication of intravenous unfractionated heparin (UFH), its incidence in medical patients treated with subcutaneous UFH is less well defined.
To determine the incidence of HIT in this category of patients, the
platelet count was performed at baseline and then every 3 ± 1 days
in 598 consecutive patients admitted to 2 medical wards and treated
with subcutaneous UFH for prophylactic (n = 360) or therapeutic
(n = 238) indications. The diagnosis of HIT was accepted in the case
of a platelet drop of 50% or more and either the demonstration of
heparin-dependent antibodies or (when this search could not be
performed) the combination of the following features: (1) the absence
of any other obvious clinical explanation for thrombocytopenia, (2) the
occurrence of thrombocytopenia at least 5 days after heparin start, and
(3) either the normalization of the platelet count within 10 days after
heparin discontinuation or the earlier patient's death due to an
unexpected thromboembolic complication. HIT developed in 5 patients
(0.8%; 95% CI, 0.1%-1.6%); all of them belonged to the subgroup of
patients who received heparin for prophylactic indications. The
prevalence of thromboembolic complications in patients with HIT (60%)
was remarkably higher than that observed in the remaining 593 patients
(3.5%), leading to an odds ratio of 40.8 (95% CI, 5.2-162.8).
Although the frequency of HIT in hospitalized medical patients treated
with subcutaneous heparin is lower than that observed in other clinical
settings, this complication is associated with a similarly high rate of thromboembolic events.
(Blood. 2003;101:2955-2959) After bleeding complications, heparin-induced
thrombocytopenia (HIT) is the most important complication of
unfractionated heparin (UFH).1-5 It develops in up to 3%
of patients treated with UFH as a consequence of an antibody-mediated
reaction against the complex heparin/platelet factor 46-9
and is associated with a high rate of venous or arterial thrombotic
events.1-5,8,10,11
Although considerable progress has been made in our understanding
of HIT, it is still unclear whether this complication occurs in all
patients treated with UFH, or it is at least partially dependent on
patient category and modality of heparin administration.4 By reviewing prospective clinical trials on the incidence of HIT in
patients receiving UFH, Chong showed a frequency of HIT ranging from
1% to 30% among patients receiving high-dose intravenous heparin,
whereas the incidence was lower than 2% in patients receiving low-dose
subcutaneous heparin.12 In a pooled analysis of a series of prospective studies evaluating the incidence of HIT, Schmitt and
Adelman estimated an incidence of 1.1% and 2.9% with the use of
intravenous porcine and bovine heparin, respectively, whereas no cases
were observed in patients treated with subcutaneous
heparin.13 By contrast, in a substudy of a recent
randomized clinical trial on the prevention of postoperative deep vein
thrombosis in orthopedic patients, HIT as confirmed by
heparin-dependent IgG antibodies developed in 2.7% of patients treated
with subcutaneous UFH,3 a rate that is fully consistent
with that reported in studies using intravenous heparin. Because the
frequency of HIT-IgG formation and the risk of HIT is highly dependent
on patient population,4 the results of this substudy do
not necessarily translate to other categories of patients.
To estimate the incidence and timing of HIT in hospitalized medical
patients requiring the administration of subcutaneous heparin for
various indications, we performed a prospective cohort study in 598 consecutive patients admitted to 2 departments of internal medicine.
All patients recruited for this investigation were followed for the
occurrence of HIT and overt clinical events.
Study design
Inception cohort
At referral, all patients included in the study had a thorough medical history obtained and underwent a physical examination with particular attention to the presence of an underlying malignancy and any previous exposure to unfractionated or low-molecular-weight heparin. In patients with medical diseases requiring the prevention of thromboembolism, prophylactic doses of heparin (ranging between 10 000 and 20 000 IU/d) were programmed for variable periods of time, usually covering the entire period of hospitalization. In most patients with acute thromboembolic disorders UFH was administered in doses able to prolong the activated partial thromboplastin time (APTT) 1.5 to 3.0 times the control value, whereas in a minority of patients lower (fixed) doses were used. In most patients UFH was given in combination with oral anticoagulant therapy, the heparin treatment being interrupted when the international normalized ratio reached a value of 2.0 or higher in 2 consecutive determinations. In a minority of patients a longer course of heparin, not followed by oral anticoagulants, was programmed. Development of HIT A platelet count was performed at baseline and thereafter every 3 ± 1 days. The diagnosis of HIT was suspected in all cases of a platelet drop of 50% or more of the pretreatment value or any further platelet count during heparin therapy, provided that this was confirmed by a second determination. When possible, a blood sample was obtained for the subsequent determination of heparin-dependent IgG antibodies. The diagnosis of HIT was accepted in the case of either the demonstration of heparin-dependent antibodies or (when this search could not be performed) the combination of the following features: (1) the absence of any other obvious clinical explanation for thrombocytopenia, (2) the occurrence of thrombocytopenia at least 5 days after heparin start, and (3) either the normalization of the platelet count within 10 days after heparin discontinuation or the earlier patient's death due to an unexpected thromboembolic complication. The first day of heparin use was calculated as day 1, and the first day that the platelet count was shown to have fallen by at least 50% was assumed to be the day of HIT occurrence.Laboratory determination of heparin-dependent antibodies Blood samples were collected from a brachial vein with a fine needle in sodium citrate 1:10, centrifuged at 10 000g for 3 minutes and stored at 70°C. Both an antigen and an activation assay
were performed according to previously described
methods.14,15 We used an antigen assay that detects IgG
antibodies against platelet factor 4 bound to polyvinylsulfonate
(Genetic Testing Institute, Brookfield, WI).14 Visual
evaluation of heparin-induced platelet activation (HIPA) was done with
the use of the HIPA assay at the Institute for Immunology and
Transfusion Medicine of Greifswald (Germany). Heat-inactivated patient
serum was incubated in a magnetic stirrer with 2 steel spheres with
washed platelets together with heparin in low and high concentration,
the transparency of the suspension being considered as a positive
result.15
Thromboembolic complications All included patients were followed until discontinuation of heparin or hospital discharge. The clinical suspicion of venous or arterial thromboembolism was confirmed by the following objective tests: compression ultrasound or venography in case of suspected deep vein thrombosis, ventilation/perfusion lung scanning, spiral computed tomography (CT) or pulmonary angiography in case of suspected pulmonary embolism, electrocardiography with enzymatic support in case of suspected myocardial infarction, and cerebral CT in case of suspected stroke. In case of death, the cause of death was either investigated by autopsy or adjudicated according to the opinion of a physician unaware of the study aims.Analysis First, we evaluated the proportion (and its 95% confidence interval [CI]) of patients who developed HIT among all those who were treated with subcutaneous UFH. Then, the cumulative frequency of HIT over time was calculated by the Kaplan-Meier technique. For this purpose, patients were censored at the third day following heparin withdrawal. Patients receiving heparin for the whole period of hospitalization were censored on the day of hospital discharge. In case of an unusual prolongation of heparin treatment, patients were censored after the completion of 45 days of observation.Odds ratios (ORs) and the 95% CIs were used to describe the association between thromboembolic complications and HIT. An OR was considered to be statistically significant when the lower limit of the 95% CI was more than 1.0.
Patients Of 949 eligible patients, 351 (37%) were excluded because of recent heparin administration (n = 140), an abnormal platelet count at baseline (n = 131), an oncohematologic disease (n = 58), liver cirrhosis (n = 11), septicemia (n = 5), concomitant chemotherapy (n = 4), or disseminated intravascular coagulation (n = 2).Therefore, 598 patients were included in the study. The main
demographic and clinical characteristics of study patients are shown in
Table 1. More than 60% of included
patients (360 of 598) received heparin for prophylactic indications.
When considering the dosage administered in the first 2 days, 87 patients (14%) received 10 000 IU daily, 303 patients (51%) 15 000
IU daily, and the remaining 208 (35%) a dosage higher than 15 000 IU
daily. Of the 598 patients, 195 patients (32.6%) had previous (at
least 3 months earlier) administration of unfractionated or
low-molecular-weight heparin.
HIT During hospitalization, 11 patients (1.8%) developed a platelet drop of at least 50%, confirmed by a second determination. Either the antigenic or the functional assay was positive in 3 of the 9 patients tested for the presence of heparin-dependent antibodies. The diagnosis of HIT was accepted also in the 2 patients in whom the antibody determination could not be done. Indeed, thrombocytopenia occurred more than 5 days after heparin start; all conditions potentially responsible for nonimmune thrombocytopenia (hemodilution from fluids/blood, sepsis, disseminated intravascular coagulation, other drug reactions, etc) could be excluded; in one patient the platelet count normalized within 1 week, and the other died in temporal association with the acute platelet fall because of an unexpected ischemic stroke. Thus, according to the predefined criteria, the rate of HIT in our cohort was 5 of 598 (0.8%; 95% CI, 0.1%-1.6%).All patients who developed HIT belonged to the group of 360 (1.4%; 95% CI, 0.5%-3.2%) who had been given heparin for
prophylactic indications. The main features of these 5 patients are
shown in Table 2 and Figure
1. HIT developed in 1 of the 87 patients (1.1%) who received an initial dose of UFH of 10 000 IU
daily, 4 of the 303 (1.3%) who received 15 000 IU daily, and in none
of the 208 (0.0%) who received an initial dose higher than 15 000 IU
daily. Previous exposure to heparin (> 3 months
earlier), which was identified in 195 patients, did not
increase the frequency of developing HIT: 0 of 195 (0.0%) versus 5 of
403 (1.2%).
No patient developed HIT within the first week. The cumulative
incidence of HIT was 0.38% (95% CI, 0%-0.95%) after 10 days, 1.04%
(95% CI, 0%-2.36%) after 15 days, 1.04% (95% CI, 0%-2.87%) after
20 days, 2.12% (95% CI, 0%-6.12%) after 1 month, and then remained
stable (Figure 2).
Symptomatic thromboembolic complications Three of the 5 patients who developed HIT (60%) experienced clinically symptomatic thromboembolic complications in temporal association with the occurrence of HIT (fatal ischemic stroke, bilateral deep venous thrombosis followed by fatal acute myocardial infarction, and acute lower limb arterial occlusion, respectively). Thromboembolic complications were recorded also in 21 patients who did not develop HIT (venous thromboembolism in 17, ischemic stroke in 2, acute myocardial infarction in 1, arterial embolism in 1), and were fatal in 2.The incidence of thromboembolic events in patients who developed HIT was remarkably higher than that observed in patients who did not (21 of 593, 3.5%; OR = 40.8; 95% CI, 5.2%-162.8%). In no patients belonging to the latter group did the platelet count decrease during or following the thromboembolic complication.
Despite the growing availability of low-molecular-weight heparins, UFH is still widely used for the prophylaxis and treatment of thrombotic disorders, especially in the United States.16-18 The results of our study show that the incidence of HIT in hospitalized medical patients treated with subcutaneous UFH (0.8%; 95% CI, 0.1%-1.6%) is lower than that observed in other settings, that is, patients treated with intravenous heparin,12,13,18 and patients treated with subcutaneous heparin for prevention of postoperative deep vein thrombosis in orthopedic surgery.3 However, it is associated with a similarly high rate of thromboembolic events. This complication peculiarly affected patients requiring a subcutaneous heparin course longer than 1 week, and its rate increased according to the duration of treatment. Noteworthy, all cases of HIT belonged to the cohort of patients who had been given heparin for prophylactic indications, whereas no cases of HIT were observed among patients requiring shorter courses of heparin for therapeutic indications. Because in recent years concern about the risk for late venous thromboembolic complications has led investigators and clinicians to consider extending the duration of prophylaxis beyond the first week in a broad spectrum of indications,16 operators should be alerted about the risk of this potentially serious complication whenever UFH is scheduled. As expected, the risk of thrombotic complications in patients developing HIT was high. Three of the 5 patients who developed HIT experienced one or more episodes of either arterial or venous thrombotic complications, which were fatal in 2. This frequency was far higher than that observed in the remaining patients of our cohort. Our data are fully consistent with those recently reported by Warkentin and associates in a surgical field3 and strongly suggest that even in hospitalized medical patients the occurrence of threatening arterial or venous thrombotic complications is to be expected in a substantial proportion of all patients who develop immune HIT. A number of methodologic issues require careful analysis. First, because we did not perform a search for heparin-dependent antibodies in all patients, we cannot exclude that the formation of IgG occurred in a proportion of patients higher than that identified. However, the purpose of our investigation was to make an estimate of the risk of clinically relevant HIT in medical inpatients receiving subcutaneous UFH. The formation of antibodies does not necessarily predict the development of this clinical syndrome.4 Second, because we labeled as having HIT also 2 patients in whom the antibody determination could not be performed, the rate of this complication might have been overestimated. However, the stringent clinical criteria we adopted in the substitution for the antibody determination makes it very likely to label these 2 patients as having HIT. Third, because at the time of planning and performing our study we were unaware of the possible delayed onset of HIT and thrombosis,19,20 patients had no further clinical and laboratory surveillance after the third day following heparin discontinuation, nor were they followed after hospital discharge. Accordingly, the rate of HIT following the administration of subcutaneous HIT in medical inpatients could be higher than that reported in the current investigation. Our study results are likely to reflect the true risk of clinically important HIT exhibited by hospitalized medical patients during the administration of subcutaneous UFH or soon after its discontinuation. The validity of our approach is confirmed by the high prevalence of unexpected thromboembolic complications among patients labeled as affected by HIT, which fully compares with that recorded in literature,1-5,8,10,11 but contrasts with that observed in the remaining patients of our cohort. We believe that the results of our study are widely applicable because consecutive patients with a broad spectrum of medical diseases requiring prophylactic or therapeutic administration of heparin were included and prospectively followed until hospital discharge. Confounding factors were minimized by excluding patients recently exposed to heparin as well as those suffering from diseases potentially responsible for nonimmune thrombocytopenia. For the definition of HIT, sensitive and specific criteria were adopted. The determination of heparin-dependent IgG antibodies was performed with the use of validated activation and antigen assays. Finally, all suspected thromboembolic events were objectively confirmed. In conclusion, our study suggests that HIT and HIT-related thromboembolic complications are relatively common adverse effects of subcutaneous UFH treatment in medical patients and are to be expected in all patients in whom heparin administration persists beyond the first week of treatment. Because this approach has become regular clinical practice in a broad spectrum of conditions essentially for prophylactic indications, we recommend close clinical and laboratory surveillance in all patients who are candidates for long courses of UFH. As an alternative, in clinical practice it is advisable to replace UFH with low-molecular-weight heparins because these compounds have been shown, at least in surgical patients, to be associated with a lower incidence of this complication, while still retaining at least a similar thromboprophylactic effect.3 We think, however, that proper clinical investigations should be done to assess the true risk of HIT in medical patients requiring long-term courses of these drugs for prophylactic indications.
Submitted July 22, 2002; accepted November 26, 2002.
Prepublished online as Blood First Edition Paper, December 12, 2002; DOI 10.1182/blood-2002-07-2201.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Paolo Prandoni, Department of Medical and Surgical Sciences, 2nd Chair of Internal Medicine, Via Ospedale Civile, 105 35128 Padua, Italy; e-mail: paoprand{at}tin.it.
1. Rhodes GR, Dixon RH, Silver D. Heparin induced thrombocytopenia with thrombotic and hemorrhagic manifestations. Surg Gynecol Obstet. 1973;136:409-416[Medline] [Order article via Infotrieve]. 2. Babcock RB, Dumper CW, Scharfman WB. Heparin-induced immune thrombocytopenia. N Engl J Med. 1976;295:237-241[Abstract]. 3. Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med. 1995;332:13301335.
4.
Warkentin TE, Sheppard JAI, Horsewood P, Simpson PJ, Moore PJ, Kelton JG.
Impact of the patient population on the risk for heparin-induced thrombocytopenia.
Blood.
2000;96:1703-1708
5.
Warkentin T, Kelton JG.
Temporal aspects of heparin-induced thrombocytopenia.
N Engl J Med.
2001;344:1286-1292 6. Amiral J, Bridey F, Dreyfus M, et al. Platelet Factor 4 complexed to heparin is the target for antibodies in heparin-induced thrombocytopenia. Thromb Haemost. 1992;68:95-96[Medline] [Order article via Infotrieve]. 7. Greinacher A, Potzsch B, Amiral J, Dummel V, Eichner A, Mueller-Eckhardt C. Heparin-associated thrombocytopenia: isolation of the antibody and characterization of a multimolecular PF4-heparin complex as the major antigen. Thromb Haemost. 1994;71:247-251[Medline] [Order article via Infotrieve]. 8. Visentin GP, Ford SE, Scott JP, Aster RH. Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells. J Clin Invest. 1994;93:81-88[Medline] [Order article via Infotrieve].
9.
Kelton JC, Smith JW, Warkentin TE, Hayward CPM, Denomme GA, Horsewood F.
Immunoglobulin G from patients with heparin-induced thrombocytopenia binds to a complex of heparin and platelet factor 4.
Blood.
1994;83:3232-3239
10.
Greinacher A, Eichler P, Lubenow N, Kwasny H, Luz M.
Heparin-induced thrombocytopenia with thromboembolic complications: meta-analysis of 2 prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range.
Blood.
2000;96:846-851 11. Warkentin TE. Clinical presentation of heparin-induced thrombocytopenia. Semin Hematol. 1998;35(suppl 5):9-16[Medline] [Order article via Infotrieve]. 12. Chong BH. Heparin induced thrombocytopenia. Aust N Z J Med. 1992;22:145-152[Medline] [Order article via Infotrieve]. 13. Schmitt BP, Adelman B. Heparin-associated thrombocytopenia: a critical review and pooled analysis. Am J Med Sci. 1993;305:208-215[Medline] [Order article via Infotrieve]. 14. Warkentin TE. Laboratory testing for heparin-induced thrombocytopenia. J Thromb Thrombolysis. 2001;10:35-45[Medline] [Order article via Infotrieve]. 15. Eichler P, Budde U, Haas S, et al. First workshop for the detection of heparin-induced antibodies: validation of the heparin-induced platelet activation test (HIPA) in comparison with PF4/heparin ELISA. Thromb Haemost. 1999;81:625-629[Medline] [Order article via Infotrieve]. 16. Geerts WH, Heit JH, Clagett GP, et al. Prevention of venous thromboembolism. Chest. 2001;119(suppl):132-175[CrossRef]. 17. Caprini JA, Arcelus J, Sehgal LR, Cohen EB, Reyna JJ. The use of low molecular weight heparins for the prevention of postoperative venous thromboembolism in general surgery. A survey of practice in the United States. Int Angiol. 2002;21:78-85[Medline] [Order article via Infotrieve]. 18. Hirsh J, Warkentin TE, Shaughnessy SG, et al. Heparin and low-molecular-weight heparin: mechanism of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest. 2001;119(suppl):64-94[CrossRef].
19.
Rice L, Attisha WK, Drexler A, Francis JL.
Delayed-onset heparin-induced thrombocytopenia.
Ann Intern Med.
2002;136:210-215
20.
Warkentin TE, Kelton JG.
Delayed-onset heparin-induced thrombocytopenia and thrombosis.
Ann Intern Med.
2001;135:502-506
© 2003 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
 |
|
  T. W. Rice and A. P. Wheeler Coagulopathy in Critically Ill Patients: Part 1: Platelet Disorders Chest, December 1, 2009; 136(6): 1622 - 1630. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Pollack Heparin-Induced Thrombocytopenia Chest, December 1, 2009; 136(6): 1703 - 1704. [Full Text] [PDF]
|
|
|
|
 |
|
 G. F. Pineo and R. D. Hull Economic and Practical Aspects of Thromboprophylaxis With Unfractionated and Low-Molecular-Weight Heparins in Hospitalized Medical Patients Clinical and Applied Thrombosis/Hemostasis, October 1, 2009; 15(5): 489 - 500. [Abstract] [PDF]
|
|
|
|
|
|
I. Elalamy, G. Le Gal, F. Nachit-Ouinekh, A. Lafuma, C. Emery, C. Le-Fur, and F. Chapuis Heparin-Induced Thrombocytopenia: An Estimate of the Average Cost in the Hospital Setting in France Clinical and Applied Thrombosis/Hemostasis, August 1, 2009; 15(4): 428 - 434. [Abstract] [PDF]
|
|
|
|
|
|
E. Shantsila, G. Y. H. Lip, and B. H. Chong Heparin-Induced Thrombocytopenia: A Contemporary Clinical Approach to Diagnosis and Management Chest, June 1, 2009; 135(6): 1651 - 1664. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. E. Warkentin, A. Greinacher, A. Koster, and A. M. Lincoff Treatment and Prevention of Heparin-Induced Thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 340S - 380S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Demir, E. Duran, O. Yigitbasi, O. Vural, T. Kurum, M. Yuksel, B. Turgut, J. M. Walenga, and J. Fareed Incidence of Antiheparin-Platelet Factor 4 Antibodies and Heparin-Induced Thrombocytopenia in Turkish Patients Undergoing Cardiac Surgery Clinical and Applied Thrombosis/Hemostasis, July 1, 2007; 13(3): 279 - 284. [Abstract] [PDF]
|
|
|
|
 |
|
 S. Austin, H. Cohen, and N. Losseff Haematology and neurology J. Neurol. Neurosurg. Psychiatry, April 1, 2007; 78(4): 334 - 341. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Dentali, J. D. Douketis, M. Gianni, W. Lim, and M. A. Crowther Meta-analysis: Anticoagulant Prophylaxis to Prevent Symptomatic Venous Thromboembolism in Hospitalized Medical Patients Ann Intern Med, February 20, 2007; 146(4): 278 - 288. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. E. Warkentin, J.-A. I. Sheppard, C. S. Sigouin, T. Kohlmann, P. Eichler, and A. Greinacher Gender imbalance and risk factor interactions in heparin-induced thrombocytopenia Blood, November 1, 2006; 108(9): 2937 - 2941. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. L. Levine, D. McCollum, and M. J. Hursting How frequently is venous thromboembolism in heparin-treated patients associated with heparin-induced thrombocytopenia? Chest, September 1, 2006; 130(3): 681 - 687. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. M. Arepally and T. L. Ortel Heparin-Induced Thrombocytopenia N. Engl. J. Med., August 24, 2006; 355(8): 809 - 817. [Full Text] [PDF]
|
|
|
|
 |
|
 L. E Efird and D. R Kockler Fondaparinux for Thromboembolic Treatment and Prophylaxis of Heparin-Induced Thrombocytopenia Ann. Pharmacother., July 1, 2006; 40(7): 1383 - 1387. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Kejariwal Heparin-induced thrombocytopenia: A COMPLICATION OF THROMBOPROPHYLAXIS J Bone Joint Surg Br, March 1, 2006; 88-B(3): 392 - 393. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Abdelkefi, L. Torjman, S. Ladeb, T. Ben Othman, W. Achour, A. Lakhal, M. Hsairi, L. Kammoun, A. Ben Hassen, and A. B. Abdeladhim Randomized Trial of Prevention of Catheter-Related Bloodstream Infection by Continuous Infusion of Low-Dose Unfractionated Heparin in Patients With Hematologic and Oncologic Disease J. Clin. Oncol., November 1, 2005; 23(31): 7864 - 7870. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. E. Warkentin and A. Greinacher Unfractionated LMWH and the risk of HIT: are medical patients different? Blood, November 1, 2005; 106(9): 2931 - 2932. [Full Text] [PDF]
|
|
|
|
|
|
P. Prandoni, S. Siragusa, B. Girolami, F. Fabris, and for the BELZONI Investigators Group The incidence of heparin-induced thrombocytopenia in medical patients treated with low-molecular-weight heparin: a prospective cohort study Blood, November 1, 2005; 106(9): 3049 - 3054. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. C. Spyropoulos Emerging Strategies in the Prevention of Venous Thromboembolism in Hospitalized Medical Patients Chest, August 1, 2005; 128(2): 958 - 969. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I.-K. Jang and M. J. Hursting When Heparins Promote Thrombosis: Review of Heparin-Induced Thrombocytopenia Circulation, May 24, 2005; 111(20): 2671 - 2683. [Full Text] [PDF]
|
|
|
|
 |
|
 C. Pohl, A. Kredteck, B. Bastians, P. Hanfland, T. Klockgether, and U. Harbrecht Heparin-induced thrombocytopenia in neurologic patients treated with low-molecular-weight heparin Neurology, April 12, 2005; 64(7): 1285 - 1287. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. E. Warkentin New Approaches to the Diagnosis of Heparin-Induced Thrombocytopenia Chest, February 1, 2005; 127(2_suppl): 35S - 45S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. F. Pineo and R. D. Hull Low-Molecular-Weight Heparin for the Treatment of Venous Thromboembolism in the Elderly Clinical and Applied Thrombosis/Hemostasis, January 1, 2005; 11(1): 15 - 23. [Abstract] [PDF]
|
|
|
|
|
|
T. E. Warkentin Heparin-Induced Thrombocytopenia: Diagnosis and Management Circulation, November 2, 2004; 110(18): e454 - e458. [Full Text] [PDF]
|
|
|
|
|
|
T. E. Warkentin and A. Greinacher Heparin-Induced Thrombocytopenia: Recognition, Treatment, and Prevention: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest, September 1, 2004; 126(3_suppl): 311S - 337S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. H. Geerts, G. F. Pineo, J. A. Heit, D. Bergqvist, M. R. Lassen, C. W. Colwell, and J. G. Ray Prevention of Venous Thromboembolism: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest, September 1, 2004; 126(3_suppl): 338S - 400S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Writing Committee for the Galilei Investigators Subcutaneous Adjusted-Dose Unfractionated Heparin vs Fixed-Dose Low-Molecular-Weight Heparin in the Initial Treatment of Venous Thromboembolism Arch Intern Med, May 24, 2004; 164(10): 1077 - 1083. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U. Harbrecht, B. Bastians, A. Kredteck, P. Hanfland, T. Klockgether, and C. Pohl Heparin-induced thrombocytopenia in neurologic disease treated with unfractionated heparin Neurology, February 24, 2004; 62(4): 657 - 659. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. B. Cines, J. B. Bussel, R. B. McMillan, and J. L. Zehnder Congenital and Acquired Thrombocytopenia Hematology, January 1, 2004; 2004(1): 390 - 406. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. E. Warkentin, W. C. Aird, and J. H. Rand Platelet-Endothelial Interactions: Sepsis, HIT, and Antiphospholipid Syndrome Hematology, January 1, 2003; 2003(1): 497 - 519. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2003 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
Top
Abstract
Introduction
